Back to Search Start Over

Hypermethylation Of ADHFE1 Promotes The Proliferation Of Colorectal Cancer Cell Via Modulating Cell Cycle Progression.

Authors :
Hu YH
Ma S
Zhang XN
Zhang ZY
Zhu HF
Ji YH
Li J
Qian XL
Wang YX
Source :
OncoTargets and therapy [Onco Targets Ther] 2019 Oct 04; Vol. 12, pp. 8105-8115. Date of Electronic Publication: 2019 Oct 04 (Print Publication: 2019).
Publication Year :
2019

Abstract

Background: Colorectal cancer (CRC) is one of the most common malignancies worldwide. Studies have demonstrated that epigenetic modifications play essential roles in the development of CRC. ADHFE1 is a differentially expressed gene that has been reported to be hypermethylated in CRC. However, the role and mechanism of ADHFE1 in the proliferation of CRC remain unclear.<br />Materials and Methods: ADHFE1 expression was analyzed in CRC tissues by IHC and qRT-PCR, and the relationship between ADHFE1 expression and the clinicopathological parameters was analyzed. Cell proliferation were assessed by the in vitro and in vivo experimental models. GSEA assay was performed to explore the mechanism of ADHFE1 in the proliferation of CRC. Flow cytometry and Western blot were used to detect the activation of the cell cycle signaling. Bisulfite genomic sequence (BSP) assay was used to test the methylation degree of ADHFE1 gene promoter in CRC tissues.<br />Results: Here, we verified that ADHFE1 was down-regulated and hypermethylated in CRC tissues. The down-regulation of ADHFE1 was correlated with poor differentiation and advanced TNM stage of CRC patients. And ADHFE1 expression restored when the CRC cell line SW620 was treated with the demethylating agent 5-Aza-CdR. Overexpression of ADHFE1 inhibited the proliferation of CRC, while ADHFE1 knockdown promoted the proliferation of CRC cells in vitro and in vivo. Moreover, ADHFE1 overexpression could induce a significant G1-S cell cycle arrest in CRC cells and vice versa.<br />Conclusion: Hypermethylation of ADHFE1 might promote cell proliferation by modulating cell cycle progression in CRC, potentially providing a new therapeutic target for CRC patients.<br />Competing Interests: The authors report no conflicts of interest in this work.<br /> (© 2019 Hu et al.)

Details

Language :
English
ISSN :
1178-6930
Volume :
12
Database :
MEDLINE
Journal :
OncoTargets and therapy
Publication Type :
Academic Journal
Accession number :
31632063
Full Text :
https://doi.org/10.2147/OTT.S223423